NM_000132.4(F8):c.508C>T (p.Pro170Ser)

For F8 c.508C>T (p.Pro170Ser), a pathogenic missense variant in the A1 domain of Factor VIII that likely disrupts protein folding and secretion, emicizumab (Hemlibra) — a bispecific monoclonal antibody bridging activated Factor IX (FIXa) and Factor X (FX) — represents the current standard of care for prophylaxis. Emicizumab is variant-agnostic: it bypasses the need for functional FVIII entirely by mimicking the cofactor function of FVIIIa in the tenase complex. For a missense variant like p.Pro170Ser in the A1 domain, the reduced FVIII activity may result from impaired secretion, accelerated clearance, or reduced FIXa binding. Regardless of the specific molecular mechanism, emicizumab provides consistent hemostatic protection independent of endogenous FVIII status.

Emicizumab was approved by FDA in 2017 (initially for inhibitor patients) and expanded to all severe hemophilia A patients (HAVEN trials). The HAVEN 1-4 trials demonstrated that subcutaneous emicizumab prophylaxis achieves annualized bleed rates of 1.5 treated bleeds/year (HAVEN 3; Mahlangu et al., NEJM 2018; PMID:30157389), superior to on-demand FVIII and non-inferior to FVIII prophylaxis, with the advantage of subcutaneous administration every 1-4 weeks versus IV FVIII infusions 2-3 times weekly. For p.Pro170Ser, Pro170 is located in the A1 domain of FVIII, which participates in FIXa binding within the tenase complex. Proline at position 170 is likely critical for maintaining the A1 domain beta-turn structure; substitution with serine introduces hydroxyl-mediated hydrogen bonding potential that may alter local folding. ClinVar classifies this variant as Pathogenic. Importantly, emicizumab is particularly valuable for hemophilia A patients who develop inhibitory antibodies against FVIII replacement therapy — a complication occurring in 25-30% of severe hemophilia A patients — since it is structurally unrelated to FVIII and is not neutralized by FVIII inhibitors.

Emicizumab does not provide complete hemostatic normalization — it mimics only the procoagulant cofactor function of FVIIIa and does not replicate FVIII regulatory interactions (e.g., thrombin-mediated activation/inactivation kinetics). Breakthrough bleeds still occur, particularly with high-injury-risk activities or surgical procedures, requiring supplemental bypassing agents. Concurrent use of activated prothrombin complex concentrate (aPCC/FEIBA) with emicizumab carries a risk of thrombotic microangiopathy, necessitating careful management protocols. Laboratory monitoring is complicated because emicizumab interferes with standard aPTT-based coagulation assays, requiring chromogenic FVIII assays with bovine reagents for accurate FVIII measurement. Long-term immunogenicity (anti-drug antibodies against emicizumab) has been observed in a small percentage of patients. For p.Pro170Ser specifically, if the variant produces partially functional FVIII with reduced but measurable activity (moderate hemophilia A phenotype), the incremental benefit of emicizumab prophylaxis over FVIII replacement should be weighed against cost (~$500K/year). Gene therapy (AAV-FVIII) may offer a curative alternative for patients without FVIII inhibitors.